PMID- 30154096
OWN - NLM
STAT- MEDLINE
DCOM- 20190307
LR  - 20240210
IS  - 1470-8752 (Electronic)
IS  - 0300-5127 (Print)
IS  - 0300-5127 (Linking)
VI  - 46
IP  - 5
DP  - 2018 Oct 19
TI  - The role of mTOR-mediated signals during haemopoiesis and lineage commitment.
PG  - 1313-1324
LID - 10.1042/BST20180141 [doi]
AB  - The serine/threonine protein kinase mechanistic target of rapamycin (mTOR) has 
      been implicated in the regulation of an array of cellular functions including 
      protein and lipid synthesis, proliferation, cell size and survival. Here, we 
      describe the role of mTOR during haemopoiesis within the context of mTORC1 and 
      mTORC2, the distinct complexes in which it functions. The use of conditional 
      transgenic mouse models specifically targeting individual mTOR signalling 
      components, together with selective inhibitors, have generated a significant body 
      of research emphasising the critical roles played by mTOR, and individual mTOR 
      complexes, in haemopoietic lineage commitment and development. This review will 
      describe the profound role of mTOR in embryogenesis and haemopoiesis, 
      underscoring the importance of mTORC1 at the early stages of haemopoietic cell 
      development, through modulation of stem cell potentiation and self-renewal, and 
      erythroid and B cell lineage commitment. Furthermore, the relatively discrete 
      role of mTORC2 in haemopoiesis will be explored during T cell development and B 
      cell maturation. Collectively, this review aims to highlight the functional 
      diversity of mTOR signalling and underline the importance of this pathway in 
      haemopoiesis.
CI  - (c) 2018 The Author(s).
FAU - Malik, Natasha
AU  - Malik N
AD  - Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, 
      University of Glasgow, Glasgow, U.K.
FAU - Sansom, Owen J
AU  - Sansom OJ
AD  - Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, 
      University of Glasgow, Glasgow, U.K.
AD  - Cancer Research UK Beatson Institute, Garscube Estate, Glasgow, U.K.
FAU - Michie, Alison M
AU  - Michie AM
AUID- ORCID: 0000-0002-5404-475X
AD  - Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, 
      University of Glasgow, Glasgow, U.K. Alison.Michie@glasgow.ac.uk.
LA  - eng
GR  - 21139/CRUK_/Cancer Research UK/United Kingdom
GR  - MR/K014854/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180828
PL  - England
TA  - Biochem Soc Trans
JT  - Biochemical Society transactions
JID - 7506897
RN  - 0 (Lipids)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 2)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - B-Lymphocytes/cytology
MH  - *Cell Lineage
MH  - *Cell Proliferation
MH  - Cell Survival
MH  - Erythrocytes/cytology
MH  - *Hematopoiesis
MH  - Hematopoietic Stem Cells/cytology
MH  - Humans
MH  - Lipids/chemistry
MH  - Mechanistic Target of Rapamycin Complex 2/metabolism
MH  - Mice
MH  - Mice, Knockout
MH  - *Mice, Transgenic
MH  - Myeloid Cells/cytology
MH  - *Signal Transduction
MH  - Stem Cells/cytology
MH  - T-Lymphocytes/cytology
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC6195642
OTO - NOTNLM
OT  - haemopoiesis
OT  - intracellular signalling
OT  - mechanistic target of rapamycin
COIS- The Authors declare that there are no competing interests associated with the 
      manuscript.
EDAT- 2018/08/30 06:00
MHDA- 2019/03/08 06:00
PMCR- 2018/08/28
CRDT- 2018/08/30 06:00
PHST- 2018/05/21 00:00 [received]
PHST- 2018/07/09 00:00 [revised]
PHST- 2018/07/10 00:00 [accepted]
PHST- 2018/08/30 06:00 [pubmed]
PHST- 2019/03/08 06:00 [medline]
PHST- 2018/08/30 06:00 [entrez]
PHST- 2018/08/28 00:00 [pmc-release]
AID - BST20180141 [pii]
AID - BST-46-1313 [pii]
AID - 10.1042/BST20180141 [doi]
PST - ppublish
SO  - Biochem Soc Trans. 2018 Oct 19;46(5):1313-1324. doi: 10.1042/BST20180141. Epub 
      2018 Aug 28.